Does Remote Work Still Have a Role to Play in the Future of Australia’s Technology Workforce?
Knight Therapeutics reports Q3 results
- Finance
William Murphy- 0
- 8 minutes read
Nov. 09, 2023 8:35 AM ETKnight Therapeutics Inc. (KHTRF), GUD:CABy: Mary Christine Joy, SA News Editor
- Knight Therapeutics press release (OTCPK:KHTRF): Q3 Non-GAAP EPS of C$0.15
- Revenue of C$0.08M (+13% Y/Y)
- For fiscal 2023, Knight has updated its financial guidance on revenues and expects to generate between C$325 million to C$335 million in revenues an increase of C$15 million on the lower end and C$5 million on the upper end of the range. The adjusted EBITDA is expected to be approximately 18% of revenues.
Comments
Have a tip? Submit confidentially to our News team. Found a factual error? Report here.